Link to Full Article • U.S. RECELL® System product sales of A$4.6M for fiscal first quarter, 60% growth quarter-over-quarter • Over half of all U.S. burn centers and surgeons trained on RECELL System Valencia, Calif., USA, and Melbourne, Australia, 31 October 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 30 September, 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that its American Depositary Shares (“ADS”) have been approved to list on the Nasdaq Capital Market […]
Link to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]
Link to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 6 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019. “We are pleased to be included in the S&P/ASX 300 […]
Link to Full Article • Total revenue of A$17.0 million for fiscal year 2019 (FY19), an increase of 50% year-over-year • U.S. product sales of A$6.2 million for FY19 • U.S. product sales of A$2.9 million for fourth quarter, an increase of 32% compared to FY third quarter sales Valencia, Calif., USA, and Melbourne, Australia, […]
Link to Full Article Innovative regenerative technology using patients’ own skin cells significantly reduced size of wounds caused by diabetic foot ulcers in all patients Valencia, Calif., USA, and Melbourne, Australia, 01 July 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) a global regenerative medicine company, announced today favorable results from an open-label feasibility study […]
Link to Full Article Abstracts Showcase Research on Potential Use of RECELL® System in Regenerative Dermatology Valencia, Calif., USA, and Melbourne, Australia, June 12, 2019 —AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announces new preliminary RECELL® Autologous Cell […]
Link to Full Article Real world experience found that the RECELL System could save one US Burn Center up to USD $28MM annually Valencia, Calif., USA, and Melbourne, Australia, 16 May 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that the health economic model of the U.S. burn care pathway, developed in collaboration […]
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 15 May 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced today that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately. Tim Rooney, AVITA’s Chief […]